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KAJIAN KUALITATIF TENTANG HALANGAN DAN GALAKAN DAN 
STRATEGI UNTUK MENINGKATKAN PEMATUHAN KEPADA 
ANTIDEPRESAN DALAM KALANGAN PESAKIT LUAR DENGAN 
KECELARUAN EPISOD KEMURUNGAN MAJOR  
 
 
ABSTRAK 
 
 Kecelaruan episod kemurungan major (MDD) adalah berkaitan dengan 
kadar relaps dan perulangan yang tinggi. Salah satu cabaran utama dalam merawat 
penyakit MDD adalah pesakit tidak patuhi terhadap pengambilan ubat-ubatan. 
Objektif kajian adalah: (1) meneroka halangan dan galakan terhadap pematuhan 
kepada antidepresan dalam kalangan pesakit luar dengan penyakit MDD; (2) 
mengenalpasti strategi untuk meningkatkan pematuhan pengambilan antidepresan 
dari perspektif pelbagai pihak yang berkepentingan. Satu kajian kualitatif dengan 
menggunakan temubual secara individu yang mendalam dan berstruktur separa telah 
dijalankan dalam kajian fasa I. Tiga-puluh peserta daripada kumpulan etnik yang 
berlainan dipilih dan terlibat dalam kajian ini untuk mencapai variasi maksimum 
dalam pensampelan, dan data dikumpulkan sehingga mencapai ketepuan. Temubual 
telah dijalankan dengan menggunakan panduan topik yang disahkan dan direkod 
secara audio, disalin kata demi kata, diperiksa dan dianalisis dengan menggunakan 
‘grounded theory’. Dalam kajian fasa II, satu kajian Delphi yang melibatkan 20 ahli 
panel dari pakar-pakar perubatan, ahli farmasi, dan jururawat / pembantu perubatan 
dijalankan untuk mengesahkan senarai strategi untuk meningkatkan pematuhan 
dalam kalangan pesakit MDD. Dua pusingan soal selidik telah dilengkapkan oleh 
ahli panel untuk mencapai persetujuan bagi strategi yang dikenalpasti. Hasil daripada 
xv 
 
kajian fasa I menunjukkan bahawa 40 tema dan sub-tema telah dikenalpasti dan 
dibahagikan kepada dua kategori utama yang berkaitan dengan halangan dan galakan 
kepada pematuhan antidepresan. Halangan yang dikenalpasti: halangan yang 
khususnya berkaitan dengan pesakit (sub-dikategorikan kepada kepercayaan yang 
salah, pelupaan, sikap yang negative, dan kekurangan pengetahuan), halangan yang 
khususnya berkaitan dengan ubat-ubatan (kesan sampingan, beban pil, tempoh 
rawatan, dan kos), peruntukan penjagaan kesihatan dan sistem, halangan sosial-
budaya (kekurangan sokongan, halangan yang berkaitan dengan agama dan 
kepercayaan, dan stigma), dan halangan logistik. Galakan yang dikenalpasti: 
mempunyai pengertian terhadapt rawatan,  manfaat kesihatan yang dilihat, aktiviti 
yang selalu dijalankan, hubungan pesakit dengan ahli kesihatan, peringatan, dan 
rangkaian sokongan sosial. Untuk kajian fasa II, 33 strategi telah disenarai dan  
persetujuan telah dicapai bagi 26 strategi di kaji selidik Delphi pusingan 1. Pendapat 
ahli panel telah diambil kira untuk mengubahsuai sesetengah strategi yang tidak 
mencapai persetujuan. Akhirnya, persetujuan penuh dicapai pada pusingan 2 untuk 
membolehkan strategi dimuktamadkan. Secara kesimpulannya, penemuan kami 
menunjukkan bahawa halangan yang khususnya berkaitan dengan pesakit dan kesan 
sampingan ubat-ubatan adalah cabaran utama untuk rawatan MDD. Manfaat 
kesihatan yang dilihat dan mempunyai pengertian terhadap keperluan rawatan adalah 
galakan yang paling kerap disebut oleh pesakit. Sejumlah 30 strategi telah 
dimasukkan dalam kajian akhir yang memberi pengesahan pakar mengenai strategi  
untuk membantu menyelesaikan dan melaksanakan intervensi yang berkesan untuk 
meningkatkan tidak pematuhan di kalangan pesakit MDD. Pendekatan pelbagai 
disiplin didapati bermanfaat untuk menangani halangan utama, dan menggalakkan 
langkah-langkah untuk memudahkan pematuhan dalam kumpulan pesakit ini.  
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A QUALITATIVE STUDY ON BARRIERS AND FACILITATORS AND 
STRATEGIES TO IMPROVE ADHERENCE TO ANTIDEPRESSANTS 
AMONG OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER  
 
 
ABSTRACT 
 
 Major depressive disorder (MDD) is associated with a high rate of relapse 
and recurrence. One of the major challenges in treating MDD is patients’ non-
adherence to medication. The objectives aimed: (1) to explore the barriers and 
facilitators of patients’ adherence to antidepressants among outpatients with MDD; 
(2) to identify strategies that aimed to improve adherence from the perspective of 
various stakeholders. A qualitative study using semi-structured and individual in-
depth interviews was conducted in phase I of the study. Thirty participants were 
purposively sampled from different ethnicities to achieve maximum variation in 
sampling, and data were collected until it reached thematic saturation. Interviews 
were conducted using a validated topic guide and responses were audio-tape 
recorded, transcribed verbatim, checked, and analysed using the grounded theory 
approach. In phase II, a Delphi survey involving 20 panellists from physicians, 
pharmacists, and nurses/medical assistant; was conducted to validate a list of 
strategies that aimed to improve patients’ adherence. Panellists completed two-
rounds of self-administered questionnaires to obtain a group consensus for the 
strategies identified. Results from phase I showed that 40 different themes and sub-
themes were identified which were conceptually divided into two distinct categories 
related to barriers and facilitators to adherence. The barriers were: patient-specific 
barriers (sub-categorised into erroneous beliefs, forgetfulness, negative attitudes, and 
xvii 
 
lack of knowledge), medication-specific barriers (side effects, pill burden, treatment 
duration, and costs), healthcare provision and system, social-cultural barriers (lack of 
support, barriers related to religion and cultural beliefs, and stigma), and logistic 
barriers. The facilitators were: having insight, perceived health benefits, regular 
activities, patient-provider relationship, reminders, and social support networks. In 
phase II, there were a total of 33 strategies listed and consensus was achieved for 26 
strategies at Round 1 survey. The panellists’ opinions were taken into consideration 
when modifying the strategies that did not achieve consensus. Full consensus was 
achieved at Round 2, enabling the finalisation of the strategies. In conclusions, our 
findings suggest that patients’ specific barriers and medication side effects were the 
major challenges for the treatment of MDD. Perceived health benefits and having 
insight on the need of treatment were the most frequently cited facilitators. A total of 
30 strategies were included in the final study that provides expert confirmation on the 
strategies that help to solve and be used to implement effective interventions to 
improve non-adherence in patients with MDD. Multi-disciplinary approach was 
found beneficial to address the key barriers, and promote measures to facilitate 
adherence in this group of patients.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background of the Study 
Major Depressive Disorder (MDD) is a significant mental health problem that is 
characterised by sense of hopelessness and persistently low or depressed mood that is 
accompanied by a loss of interest or pleasure in normal enjoyable activities 
(American Psychiatric Association, 2000). The disease’s burden resulting from MDD 
is estimated to increase both in economically developed and under-developed 
countries. According to World Health Organization (WHO) health report 2001, 
depression is a major burden for the health care system worldwide in terms of health-
related quality of life, loss of working days, and increased utilisation of healthcare 
services (Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015; Greenberg et al., 
2003; World Health Organization, 2001). MDD is found to be the most prevalent 
burden that it was rated as the fourth leading disabling condition and is expected to 
be second to ischemic heart disease by the year 2020 (Murray & Lopez, 1997; Ustun, 
Ayuso-Mateos, Chatterji, Mathers, & Murray, 2004). In addition, MDD is expected 
to be the highest disorder in developed countries by the year 2030 (World Health 
Organization, 2001).  
 
Across the Asia Pacific region, the top five mental health problems are depression, 
anxiety disorder, Post-Traumatic Stress Disorder (PTSD), suicidal behaviour, and 
substance abuse disorder (OECD, 2012). Of these, depression is the top mental 
health problems contributing to 15.2 to 21.1 Disability Adjusted Life Years (DALYs) 
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per year (Samy, Khalaf, & Low, 2015). A survey conducted across the Asia Pacific 
region found that 5% of the population has MDD and up to 15% has suffered from 
depression symptoms. Of this, rates of MDD are comparable to that of the Western 
countries (Chiu, 2004). In Malaysia, depression is the most common mental illness 
reported (Mukhtar & Oei, 2011). The National Health Morbidity Survey IV (NHMS 
IV) in 2011 has showed that the prevalence of lifetime depression is 2.4% and the 
current depression rate among adults is 1.8%, which is approximately 0.3 million 
adults in Malaysia (Institute for Public Health, 2011).  
 
Patients with MDD often suffer from residual symptoms, which interfere with their 
functioning (Keller, Hirschfeld, Demyttenaere, & Baldwin, 2002). Furthermore, 
MDD constitutes a high economic and societal burden resulting from its high 
prevalence, under-diagnosed, and under-treatment (White, Vanderplas, Ory, Dezii, & 
Chang, 2003; Wu et al., 2012).  
 
One of the major challenges in treating depression is patients’ non-adherence to 
medication, which has been reported to vary from 10-60% of patients by missing 
their doses or by prematurely discontinuing their medication altogether (Bull et al., 
2002; Demyttenaere & Haddad, 2000; Keller et al., 2002; Lingam & Scott, 2002). 
This subsequently results in failure in treating patients with MDD. In addition, non-
adherence to antidepressants has been shown to result in significantly poorer clinical 
outcomes such as increased risk of relapse and recurrence, increased emergency 
department visits, and hospitalisations rates (K. H. Kim, Lee, Paik, & Kim, 2011; Liu, 
Tepper, & Able, 2011; Yau et al., 2014). This has subsequently translated to an 
increased in healthcare utilisation and charges in this subset of patients (Iuga & 
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McGuire, 2014). However, non-adherence remains a major problem in patient care, 
despite of the large number of studies conducted in this area over a decade (Al-
Qasem, Smith, & Clifford, 2011).   
 
Little is known about the attitudes and beliefs of MDD patients towards their 
antidepressants. The definitions of adherence by WHO appear to take a clinical 
perspective on patients’ behaviour towards their treatment instead of patients’ 
perceptions or experiences (World Health Organization, 2003). Patients may choose 
not to adhere to treatment because of their experiences that it is inappropriate or 
inaccessible. Thus, it would be desirable to explore further to obtain more 
information from patients on barriers and facilitators on adherence to their 
therapeutic regime as prescribed by the doctors.  
 
1.2 Statement of the Problem 
MDD is a disorder that can be reliably diagnosed and treated in the primary care 
setting (Marcus, Yasamy, van Ommeren, Chisholm, & Saxena, 2012). As outlined in 
the Malaysia Clinical Practice Guideline of MDD (Ministry of Health Malaysia, 
Malaysian Psychiatric Association, & Academy of Medicine of Malaysia, May 2007), 
antidepressants are found to effectively reducing depressive symptoms and that 
Selective Seratonin Reuptake Inhibitors (SSRIs) are drugs of first choice due to its 
better tolerability. Other newer antidepressants such as mirtazapine, venlafaxine, 
escitalopram have also been found to be efficacious. Generally, follow up should be 
done within 2 weeks of initial treatment for dose titration according to patients’ 
depressive symptoms. If patient does not show any response after 4 weeks of 
antidepressants treatment at adequate dosage, switching of antidepressants may be 
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considered. Antidepressants should be continued for at least 6-9 months after 
remission of the depressive episode to reduce the risk of relapse. Besides 
pharmacological treatment, MDD can also be managed by using psychological 
interventions such as supportive therapy, problem-solving therapy, counselling or 
cognitive behavioural therapy (CBT). Of these, CBT is considering as the 
intervention of choice for patients with moderate or severe MDD. However, 
combination of both pharmacological and psychological therapy was recommended 
when patients present with severe MDD (Ministry of Health Malaysia et al., May 
2007).  
 
MDD is a pernicious illness associated with a high rate of relapse and recurrence, 
which occurs in almost 85% of depressed patients (Murata, Kanbayashi, Shimizu, & 
Miura, 2012). The National Institute of Mental Health Consensus Development 
Conference on relapse and recurrence of depression reported that 50 to 85% of 
depressed patients will suffer an episode of recurrence during their lifetime, of these, 
50% will experience recurrence within 2 years of the initial episode (Melfi et al., 
1998). Recurrence of depression, in turn, increases the likelihood that future episodes 
will be more frequently and more severe in term of depressive symptoms and 
increase in hospitalization rates; resulting in multiple medications having to be used  
or lifelong maintenance therapy needed (Kessing, Hansen, & Andersen, 2004; 
Murata et al., 2012). In addition, recurrence of depression can have significant 
personal and public health consequences. For example, a study over 3000 MDD 
patients found that 90% of those with recurrent depression reported very much 
impairment, limiting work productivity and social interaction, and 40% sought 
professional help as a result of recurrence (Wittchen, Nelson, & Lachner, 1998).   
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Despite the proven efficacy of antidepressants, many depressed patients still do not 
receive an adequate dosage and duration of treatment, which has been frequently 
seen in both primary care and specialised settings (Al-Jumah & Qureshi, 2012). In 
addition, the reported levels of non-adherence have been consistently high; which 
remains a serious concern. Hence, there is clearly a need for a better understanding 
on why non-adherence occurs in patients with MDD in the country for effective 
interventions to facilitate adherence (Clatworthy, Bowskill, Rank, Parham, & Horne, 
2007; Delamater, 2006).  
 
A substantial literature has documented that there are several factors of being the 
cause of non-adherence such as patients’ social and demographic factors, education 
levels, poor patient-clinician interaction, negative attitudes, and culture–influenced 
beliefs (Aikens, Nease, & Klinkman, 2008; Aikens, Nease, Nau, Klinkman, & 
Schwenk, 2005; Chakraborty, Avasthi, Kumar, & Grover, 2009; A. Gabriel & C. 
Violato, 2010; Holma, Holma, Melartin, & Isometsä, 2010; Jin, Sklar, Oh, & Shu, 
2008; Anthony F. Jorm, Christensen, & Griffiths, 2005; K.-U. Lee et al., 2010). Of 
all these factors, patients’ attitudes and personal beliefs on MDD and its treatment 
are thought to differ significantly between different cultures.  
 
In contrary to the Western population, Malaysia consists of a multiracial society with 
a diversity of cultural beliefs that exists among the three main ethnic groups, namely 
the Malays, Chinese and Indians (Razali, Khan, & Hasanah, 1996). A study 
conducted at Sabah (East Malaysia) found that the Malays population tend to believe 
that mental illness behaviour is sinful and should be punished and it is usually caused 
by social stresses, that it could be treated by changing societal responsibilities 
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(Swami, Loo, & Furnham, 2010). However, the study finding might not be 
generalised to the Malays population living in Peninsular Malaysia, which has larger 
populations of Malays with more developed socio-economic status. Other studies 
showed that the Malays found mental illness is an illness of the soul that caused by 
spiritual and religious factors or as a social punishment (Haque, 2005; Parameshvara 
Deva, 2004). Among the Chinese, mental illnesses are stigmatised and are often 
attributed to ‘bad genes’ and the concept of ‘losing face’, if the patients receive 
treatment at psychiatric clinics. Thus, it is usually dealt with by folk healers such as 
the Chinese Mediums (Ariff & Beng, 2006). Among the Indians, most patients hold 
the belief that mental illnesses are the effects of ill spirits and this erroneous belief 
has directly influenced the medication adherence behaviour in Indian patients 
(Chakraborty et al., 2009). All these evidences have shown that perceptions towards 
the disease vary in different cultures. Therefore, cultural backgrounds should be 
taken into consideration when providing treatment to MDD patients. For this reason, 
it is especially important to carry out studies to explore patients’ adherence 
behaviours in our country where cultural health beliefs within that patient or 
treatment group might be a one of the contributing factor of patients’ non-adherence 
to medication.  
 
There have been studies exploring patients’ experiences in relation to other health 
problems such as hypertension and antiretroviral drug therapy, but there are limited 
studies in neurotic disorder such as depression (Ogedegbe, Harrison, Robbins, 
Mancuso, & Allegrante, 2003; Wasti, Simkhada, Randall, Freeman, & van Teijlingen, 
2012). More recently, there is a similar study conducted in Malaysia, but the study is 
aimed to explore the self-monitoring of blood glucose (SMBG) in patients with type 
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2 diabetes using insulin instead of study in psychiatric illnesses (Ong, Chua, & Ng, 
2014). Hence, the present study is needed to explore the barriers and facilitators of 
patients’ adherence to medication in mental illness.  
 
There are several studies conducted in Malaysia that have been quantitative in nature 
(Jacob, Ab Rahman, & Hassali, 2015; Tahir M. Khan, Sulaiman, & Hassali, 2010; T. 
M. Khan, Sulaiman, Hassali, & Tahir, 2009; Tahir Mehmood Khan, Sulaiman, & 
Hassali, 2009). However, using a structured set of close-ended interview instruments 
has not allowed the patients to fully express themselves and to give responses outside 
the options given on the questionnaires. The patients are unable to express in their 
own words, of their experiences of treatment, and more qualitative study in this area 
has been called for (Ariff & Beng, 2006; Razali et al., 1996).  
 
Grounded theory is defined as the discovery of a theory from data systematically 
obtained in the view of participants (Strauss & Corbin, 1998). It is a qualitative 
research design in which the researcher generates a general explanation (a theory) of 
a process, an action, or an interaction shaped by the views of the participants 
(Creswell & Creswell, 2013). In an exploratory study, only by using qualitative 
grounded theory that allowed researchers to understand the underlying reasons and to 
uncover prevalent trends in thought as well as opinions of patients from their ‘native’ 
point of view through their experiences (Al-Busaidi, 2008; Christine Brown & Lloyd, 
2001; Sbaraini, Carter, Evans, & Blinkhorn, 2011; Whitley & Crawford, 2005). This 
is particularly important in Malaysia, as there is a need for further qualitative 
research to account for the culture, religion, and socioeconomic factors that influence 
peoples’ decision in health-seeking behaviours (Tahir Mehmood Khan et al., 2009; 
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Swami et al., 2010). Therefore, we choose to conduct a qualitative study using the 
grounded theory method to explore the patients’ experiences and their adherence 
behaviours on antidepressants in Malaysian population.  
 
Qualitative studies that have been conducted thus far have either focused on general 
public or healthcare providers, as opposed to the people who are actually affected by 
the disease (W. W. Chong, Aslani, & Chen, 2013; Hanafiah & Van Bortel, 2015; 
Jang, Chiriboga, & Okazaki, 2009; Tahir M. Khan et al., 2010; T. M. Khan et al., 
2009; Tahir Mehmood Khan et al., 2009; Yeap & Low, 2009). The results of these 
studies, however, would not be generalisable to the majority of the patients’ 
population in MDD. In addition, a number of qualitative studies conducted are on 
focus group instead of individual interviews (Interian, Martinez, Guarnaccia, Vega, 
& Escobar, 2007; Uebelacker et al., 2012). This approach has a setback, as some 
patients may not be comfortable to share their experiences openly in the presence of 
other patients. Moreover, as many of the previously-published studies were 
conducted in the West that specially focused on the Latino community, the findings 
obtained might not be applicable to the Asian population (Interian et al., 2007; 
Uebelacker et al., 2012; Yeap & Low, 2009). Hence, it is crucial for a local study to 
be conducted.  
 
Till date, there are relatively few studies conducted in Malaysia that neither 
concentrate on the patients’ experience on the use of their antidepressants nor to 
explore the underlying reason for medication adherence behaviour. Therefore, this 
study aims to explore the barriers and facilitators of adherence to antidepressants in 
MDD patients. Understanding the attitudes and reasons underlying their behaviours 
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can provide valuable insights into the rationale for identifying adherence problems in 
patients with MDD. Apart from that, results obtained from the study will be of 
significance for any future attempts to develop strategies or interventions that can 
help to solve the identified adherence problems and to design a better adherence 
program that is going to cater for our Malaysian setting and culture.  
 
1.3 Objectives of the Study  
1.3.1 The General Objective: 
The general aim of this study is to explore the barriers and facilitators of patients’ 
adherence to antidepressants and to identify strategies that aimed to improve 
adherence among outpatients with MDD.  
 
1.3.2 The Specific Objectives: 
a) To explore the barriers to adherence with antidepressants among outpatients 
with MDD.   
b) To explore the facilitators to adherence with antidepressants among 
outpatients with MDD.   
c) To identify strategies that aimed to improve adherence from the perspective 
of various stakeholders.  
 
1.4 Conceptual Framework of the Study 
Many conceptual models have been used to help understanding the barriers to 
medication adherence, including the health belief model (G. R. Kelly, Mamon, & 
Scott, 1987) and Necessity-Concerns framework (Cameron & Leventhal, 2003). The 
health belief model (HBM) has been used to study the relationships between 
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patients’ health belief behaviour and medication adherence. The core component of 
this model includes perceived susceptibility, perceived severity, barriers, benefits, 
and a ‘cue to action’ which affect patients’ adherence to their medication (G. R. 
Kelly et al., 1987). In HBM, patients who are aware of and perceived the severity of 
their illness are more prone to adhere to their medication. In addition, patients who 
perceived the effectiveness and are satisfied with their current therapy would 
promote medication adherence. In contrary, the experience of adverse effects acts as 
a barrier to adherence (DiMatteo, Haskard, & Williams, 2007).  
 
The Necessity-Concerns framework is conceptualised as the patients’ perceptions of 
the necessity and need of treatment to maintain their health condition, and their 
concerns about the actual and potential adverse effects of treatment (Cameron & 
Leventhal, 2003; Rob Horne et al., 2013; Robert Horne & Weinman, 1999). The 
utility of this framework has been identified in study conducted by Aikens et al. 
(2005), which explained the adherence to maintenance-phase antidepressants as a 
function of patient beliefs about medication.   
 
While perceptions are acknowledged to be a major factor in patients who were non-
adherent to medication, however, none of these models dominates the other or fully 
explains the barriers and facilitators to medication adherence in MDD patients. Thus, 
a qualitative study using grounded theory approach is conducted to explore the 
barriers and facilitators of adherence to antidepressants in patients with MDD. Based 
on the identified barriers and also from the literature review, a list of strategies to 
improve antidepressants’ adherence will be listed using the Delphi technique to 
overcome the barriers of adherence in MDD.  
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1.5 Significance 
In brief, the results and findings from this study could be used in the following 
manner: 
 
Table 1.1  
Potential Application and Impact of the Study 
 Government  
 
(MOH, Malaysia) 
 To review and  alter healthcare practices which might 
affect patients’ adherence behaviour 
 
To develop mental health  programs that facilitate 
antidepressants medication adherence by taking into 
account the different cultural, religion and 
socioeconomic barriers 
 
Mental health care 
provider 
 
(psychiatrists, medical 
officer at psychiatric 
department, 
psychologists, 
counsellors)                 
To modify interventions that facilitate adherence 
 
To focus more on the facilitators of adherence that are 
identified from the study and apply in the practice 
when treating MDD patients 
 
 
Pharmacists  
 
(MTAC or clinical 
pharmacist at psychiatric 
department) 
To develop specific counselling protocols that are 
patient-centered by taking into account the different 
beliefs and attitudes that affect the health-seeking 
behaviour of MDD patients  
 
The identified adherence problem can be used as a 
guide to deal with depressed patients to ensure 
patients’ adherence 
 
 
Patients  
 
(who taking 
antidepressants 
medication) 
 
To obtain utmost benefit from the strategies or 
interventions that are implemented by the government, 
mental health care provider and the pharmacist, based 
on the result obtained from the study 
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1.6 Chapter Outline 
A brief outline of the chapter for this thesis is as follows: 
 
Chapter 2 – This chapter reviews the existing literature relating to the study 
objectives. This chapter is organised into four sections: Firstly, the literature on 
factors associated with antidepressants non-adherence among patients with MDD is 
presented in which it is sub-organised into patient-specific factors, medication-
specific factors, socio-cultural related factors, healthcare provision and system 
related factors, and disease related factors. Secondly, literature on impacts of non-
adherence to antidepressants among patients with MDD is presented, which focuses 
on clinical, economic, and humanistic impacts. Thirdly, strategies/intervention to 
improve adherence to antidepressants among patients with MDD is reviewed. Lastly, 
the overviews of consensus methods are presented relating to the objectives for the 
phase II of the study.  
  
Chapter 3 – This chapter presents and justifies the methodology used in the study. 
This chapter is divided into two parts: (1) Phase I: Exploring the barriers and 
facilitators of patients’ adherence to antidepressants among outpatient with MDD; (2) 
Phase II: Identifying list of strategies that aimed to improve patients’ adherence to 
antidepressants among outpatient with MDD. Each phase begins with the study 
design and a description of the setting in which the study took place. It is followed by 
discussion on the study population which has included the sample size and sampling 
method used. Finally, the study procedure is presented in the form that includes the 
manner in which the data was collected and a short discussion on the data analyses.   
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Chapter 4 – The results for phase I and phase II of the study are presented in this 
chapter. In phase I, the socio-demographic characteristics of patients are presented. 
The themes for barriers and facilitators are organised into two distinct categories. For 
the barriers to antidepressants adherence, they are sub-categorised into five 
categories: (1) patient-specific barriers, (2) medication-specific barriers, (3) 
healthcare provision and system, (4) socio-cultural barriers, and (5) logistic barriers. 
For facilitators to antidepressants adherence, they are sub-categorised into six 
categories: (1) illness-related factors, (2) perceived health benefits, (3) regular 
activities, (4) Patient-provider relationship, (5) reminders, and (6) social support 
networks. In phase II, the Delphi results will be presented in two sections: (1) Round 
1, and (2) Round 2; at which demographic characteristics of panellists and consensus 
agreement of the strategies are included in each of the section.      
 
Chapter 5 – The discussion for phase I and phase II of the study is presented in this 
chapter. In phase I, the findings for barriers and facilitators of adherence to 
antidepressants are discussed in comparing with various studies in the field. It is 
followed by discussion on the strategies that achieved consensus of disagreement and 
agreement in phase II of the study.  
 
Chapter 6 – This final chapter presents a summary of the study. It is followed by the 
discussion on strengths and limitations of the study. The implications of the findings 
in the context of current Malaysia mental health policy and recommendation for 
future research are also presented in this chapter.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
This chapter reviews some of the literature relating to the various factors associated 
with non-adherence to antidepressants in patients with MDD in an outpatient setting. 
The impacts of non-adherence to antidepressants are also discussed in this chapter. 
By having knowledge on the dire consequences of patients’ non-adherence, it is of 
utmost importance to understand the barriers of treatment non-adherence in patients 
with depression. Furthermore, knowing the reasons of non-adherence to 
antidepressants in patients with MDD would provide directions for designing 
effective intervention program that aims to tackle the non-adherence problems. 
Therefore, the strategies or interventions that aim to tackle the issue of patients’ non-
adherence in the treatment of MDD have also been reviewed. Lastly, the overviews 
of consensus methods are reviewed to support the importance of Delphi method used 
in answering the research question for phase II of the current study.  
 
2.1 Factors Associated with Antidepressants Non-adherence among Patients 
with MDD  
Non-adherence to antidepressants is perceived to be a complex problem in patients 
with MDD, due to multiple contributing factors. It is crucial to understand the 
reasons why MDD patients may or may not take their medication. Thus, several 
studies have been conducted to assess which specific factors influence adherence to 
antidepressants amongst patients with MDD. According to the American College of 
Preventive Medicine (2011) and WHO (2003), the factors associated with non-
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adherence in patients with depression are classified into five domains: patient-
specific factors, medication-specific factors, socio-cultural related factors, healthcare 
provision and system related factors, and disease related factors. 
 
2.1.1 Patient-specific Factors 
Patients with MDD tend to believe that regular usage of antidepressants could result 
in long-term adverse effects, so antidepressants are needed only when their 
depressive symptoms get worse, and that antidepressants are addictive and may 
cause dependence. This misconception tends to negatively affect patients’ acceptance 
of their treatment (Chakraborty et al., 2009; Jacob et al., 2015; Tamburrino, Nagel, 
Chahal, & Lynch, 2009).   
 
Jacob et al. (2015) conducted a 6-month study to determine the attitudes and beliefs 
of 104 patients with depression toward their illness and its treatment in an out-patient 
setting of a government-run hospital in Malaysia. Of the 104 patients, 40% of the 
participants believe that antidepressants are addictive and 59% believe that it would 
be difficult to discontinue the treatment if they are taking their antidepressants for a 
long term. This is mainly due to the misconception with regard to treatment of MDD, 
as most patients tend to confuse antidepressants with tranquilizers. Tranquilizers also 
known as ‘sleeping pills’, which have the same drowsy effect like antidepressants, 
but tranquilizers have the potential for addiction (Angermeyer & Matschinger, 1996). 
In addition, certain antidepressants, such as Mirtazepine, are needed to be tapered off 
slowly over several days to weeks instead of to be stopped abruptly. Therefore, many 
patients tend to misunderstand that it is difficult to discontinue the treatment if they 
have taken it for a long period of time.    
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In India, Chakraborty et al. (2009) conducted a study on 50 patients with depression 
and who were taking antidepressants to assess their attitudes and beliefs on treatment 
adherence. In the study, antidepressants compliance questionnaire (consisted of four 
components) was used as a scale together with a treatment adherence questionnaire 
to measure patients’ attitudes and beliefs towards antidepressants and treatment 
adherence. The results have shown that 88% of patients believed that antidepressants 
can alter their personality, whereas 72% of patients felt that fewer tablets could be 
taken on days when they felt their depressive symptom has improved (Chakraborty et 
al., 2009). It is very common that when patients are asymptomatic, they waiver in 
their adherence to treatment and vice versa; which has also been proven by the study 
conducted  by Tamburrino et al. (2009). Hence, patients’ attitudes and beliefs play an 
important role in determining the adherence pattern in MDD. Further exploration in 
this area should be acknowledged as an important issue in the treatment of MDD.   
 
A cross-sectional study that was conducted among 239 patients at the psychiatric 
out-patient department of a tertiary hospital in Kolkata, India showed that simply 
forgetting to take the prescribed medication is the most common reported factor of 
non-adherence to antidepressants; which has been mentioned by more than half of 
the patients (56.5%) in the study (Banerjee & Varma, 2013). This scenario is the 
same throughout the world where there are studies conducted in the non-Asian 
countries which reported that forgetfulness has been acknowledged as the factor that 
makes it difficult for patients adhering to antidepressants, which was seen in 75% of 
patients in a study conducted in Canada, 43% in a study conducted in United States 
(US), and 35% of the patients in a study conducted in Spain (Ashton, Jamerson, W, 
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& Wagoner, 2005; Bulloch & Patten, 2010; M. J. Martin et al., 2009; Tamburrino et 
al., 2009).  
 
2.1.2 Medication-specific Factors 
There are substantial researches that demonstrated medication side effects are the 
predominant factor associated with antidepressants non-adherence in patients with 
MDD (Alekhya, Sriharsha, Priya Darsini, Reddy, & Venkata Ramudu, 2015; C. 
Anderson & Roy, 2013; Ashton et al., 2005; W. W. Chong et al., 2013; De las 
Cuevas, Penate, & Sanz, 2014; Feetam, 2009a; van Servellen, Heise, & Ellis, 2011), 
which are discussed as follows.   
 
Alekhya et al. (2015) conducted a cross-sectional study among 103 patients aimed to 
determine the factors that influenced patients’ adherence to the treatment of 
depression. Drug attitude inventory (DAI) scores were used as adherence rating 
scales to measure patients’ adherence in the study (Hogan, Awad, & Eastwood, 
1983). The results have revealed that the overall non-adherence rate is high (70%) 
and that medication side effects significantly influence the mean DAI (p=0.007, t-
test) where more patients become non-adherent due to this reason.  
 
De las Cuevas et al. (2014) conducted a study among 145 patients to identify the 
determinants of non-adherence in patients with mood disorders and who were taking 
antidepressants. It was found that all patients in the study experienced drug-induced 
side effects (e.g.: drowsiness, dry mouth, insomnia, constipation, and weight gain) 
which were clearly related to the pharmacological action of antidepressants (Ministry 
of Health Malaysia et al., May 2007). However, patients who were non-adherent 
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claimed that they experienced more frequent and more intense adverse effects as 
compared to patients who were adherent, which subsequently contributed to 
premature discontinuation of antidepressants therapy in this group of patients.   
 
In Australia, Chong et al. (2013) conducted a qualitative study to explore healthcare 
providers’ views and perspectives on issues of antidepressants non-adherence in 
clinical practice. It was found that majority of the participants acknowledged 
antidepressants adverse reaction, such as sexual dysfunction, sleep disturbance, and 
weight gain, was the main contributor for non-adherence to treatment. Although the 
data collected was only based on participants’ self-reports and was not verified 
against their actual clinical behaviours or in real patients, the findings are somehow 
useful in designing future intervention programs to improve adherence in patients 
with MDD.      
 
Similarly, a survey was conducted with 350 patients with depression in New York, 
US where 42-specific questions were asked to assess reasons for non-adherence to 
antidepressants treatment (Ashton et al., 2005). The result obtained has shown that 
adverse effects, such as lost of sexual desire (23%), tiredness (18%), and weight gain 
(16%), were accounted for the second most common factor associated with patients’ 
non-adherence to their antidepressants. The patients also mentioned that the adverse 
effects that they experienced were intolerable, as it did not resolve with time and had 
significantly compromised their quality of life. Hence, they decided to discontinue 
their antidepressants prematurely due to this reason.       
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Anderson and Roy (2013) performed a secondary qualitative analysis on 80 
interviews from Healthtalkonline to further explored patients’ experiences of using 
antidepressants for depression. It was found that patients who were non-adherent to 
antidepressants were most likely driven by the experience of adverse effects such as 
sexual dysfunction, dry mouth, dizziness, weight gain, sleep disturbance and inability 
to concentrate to routine work.  
 
A systematic literature review study on factors associated with antidepressants non-
adherence also showed that one in four patients discontinued their antidepressants 
medication due to specific side effects that were examined in a descriptive study (van 
Servellen et al., 2011). Similarly, a review on medicine taking behaviour in 
depression reported side effects such as sexual dysfunction (40%), weight gain (27%) 
and daytime drowsiness (21%) were the most common reasons for antidepressants 
non-adherence in a patient survey (Feetam, 2009a).  
 
In conclusion, antidepressants side effects such as weight gain, sexual dysfunction, 
and drowsiness are the most common medication-specific factor that contributed to 
patients’ non-adherent to their treatment; which was reported in almost all of the 
study discussed in this section. In fact, healthcare provider should inform and 
counsel patients on the expected side effects of antidepressants prior to starting 
treatment, as having information about side effects supports patients’ confidence in 
treatment and subsequently prevent early discontinuation of treatment in MDD (C. 
Anderson & Roy, 2013). Collaborative care from both physician and pharmacist to 
perform pharmaceutical care and individualizing antidepressants therapy according 
to patients’ needs by prescribing the lowest effective dose which might have lower 
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risk of adverse effects, which in turn, enhance patients’ adherence to treatment of 
MDD is needed (K. Kelly, Posternak, & Jonathan, 2008).  
 
2.1.3 Socio-cultural Related Factors 
Stigma associated with both having depression and taking antidepressants was found 
by most of the studies as one of the significant factors that affects patients’ 
acceptance of their diagnosis and subsequently resulted in non-adherence to 
treatment (W. W. Chong et al., 2013; Interian et al., 2007; Jang et al., 2009; 
Uebelacker et al., 2012). Stigma has been prominently seen as a barrier to treatment 
of depression in the Latino community as compared to non-Hispanic whites in the 
US. A qualitative analyses of six focus groups interviews on Latino outpatients 
receiving antidepressants (N=30) showed that Latinos have greater stigma concerns 
than whites that they tend to discontinue their antidepressants, before seeking 
employment, as they are afraid of being negatively evaluated, as a result of 
antidepressants treatment (Interian et al., 2007). Similarly, stigma from the 
community was found to be the first theme cited as a barrier to treatment in 
depressed Latinos in study conducted by Uebelacker et al. (2012). Apart from that, 
stigma was also observed in other populations such as in Australian and Korean 
American adults (W. W. Chong et al., 2013; Jang et al., 2009).      
 
The lack of support networks particularly the family members was also noted as one 
of the contributing factors for antidepressants non-adherence in patients with MDD 
(Banerjee & Varma, 2013; Interian et al., 2007; van Grieken et al., 2014). This is 
supported by a study conducted in Latino outpatients in the US where patients 
mentioned that taking antidepressants seemed to be disapproved by their family and 
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social support system, which directly influenced them on whether to continue their 
antidepressants (Interian et al., 2007). In addition, the lack of social support such as 
reminders to take medications and nobody there to accompany patients to the 
hospital for clinic visits were among the reasons for antidepressants discontinuation 
(Banerjee & Varma, 2013). An in-depth interviews conducted by van Grieken et al. 
(2014) found that most participants revealed that insufficient support and information 
from their treating physicians would hinder them to adhere to their treatment.  
 
Similarly, stigmatising attitudes and discriminatory behaviours towards people with 
mental illness have been shown to hinder patients from seeking helps or treatment for 
their illness in Asian population, which particularly seen in Malaysian society 
(Hanafiah & Van Bortel, 2015; T. M. Khan, Hassali, Tahir, & Khan, 2011; Minas, 
Zamzam, Midin, & Cohen, 2011; Yeap & Low, 2009). For example, a cross-
sectional study conducted by Khan et al. (2011) to evaluate the public perception 
towards the causes of mental illness has revealed that regardless of ethnicity, 
Malaysian believe in supernatural reasons ,such as possession by spirits, are regarded 
as the cause of mental illness (p=0.05). The respondents also mentioned that people 
with mental illness are unfriendly, moody, dangerous, and unpredictable, hence, 
people are fearful of those who are perceived as mentally ill patients.  
 
Till to date, most of the studies that reported on stigma as the barrier to medication 
adherence are associated with mental problems such as schizophrenia and there is 
little evidence found that specifically focuses on depression (Hudson et al., 2004; 
Sajatovic & Jenkins, 2007). If any, majority of the studies focused on the Latino 
population (Interian et al., 2007; Uebelacker et al., 2012); which may limit its 
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generalisability to Asian multi-racial population. This highlights the need for more 
studies to be conducted in the Asian population.  
 
2.1.4 Healthcare Provision and System Related Factors 
There has been a broad acceptance that the nature of the patient-provider relationship 
has an important impact upon the outcomes of treatment and it served as a predictor 
of treatment adherence in patients with MDD (C. Anderson & Roy, 2013; W. W. 
Chong et al., 2013; van Grieken et al., 2014). Van Grieken et al. (2014) conducted an 
in-depth interviews in a purposive sample with 27 patients with MDD and found that 
the lack of trust in the treating physician, and insufficient information about 
treatment and support from the physician were cited by majority of the patients and 
that resulted in a hesitation to begin treatment and to continue with it. 
Correspondingly, a secondary qualitative analysis of patients’ experiences of using 
antidepressants for depression was carried out and the results showed that patients 
who discontinued their antidepressants were likely to have unsatisfactory rapport 
with their treating physician (C. Anderson & Roy, 2013). Furthermore, poor patient-
provider relationship was also described by a few participants as the factor for 
antidepressants non-adherence in study conducted by Chong et al. (2013). Thus, the 
patient-doctor partnership has been shown to be essential for patients to adhere to 
their treatment in MDD.  
 
Apart from patient-physician partnership, the lack of accessibility and availability of 
healthcare facility and system may also cause difficulties in adherence to treatment. 
In India, Banerjee and Varma (2013) developed a semi-structured interview schedule 
to further explore the factors hindering adherence in 193 patients who reported 
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having difficulty in adhering with the prescribed antidepressants from a cross-
sectional study. The authors found that health-facility related factors such as long 
distance from home to hospital (47.7%) and long waiting time in the hospital (31.6%) 
were the reasons for therapy discontinuation.  
 
Despite of a comprehensive search on the literature, it is found that there is limited 
study that focused on healthcare system and facilities related factor associated with 
treatment adherence in depression. There was a review study conducted to explore 
and evaluate factors affecting therapeutic compliance which reported that lack of 
accessibility to healthcare, long waiting time for clinic visits, and difficulty in getting 
a refill have all contributed to patients’ non-adherence to treatment; but that study 
was not specifically conducted on patients with depression who were taking 
antidepressants (Jin et al., 2008). Hence, there is a need for more studies to be 
conducted that focus in this area for patients with MDD.    
 
2.1.5 Disease Related Factors 
Indeed, depression itself has been shown to be a contributing factor for non-
adherence (DiMatteo, Lepper, & Croghan, 2000). This is because patients with 
depression often have impaired cognitive focus, energy and motivation that might be 
expected to affect their willingness and ability to follow through the treatment (Bull 
et al., 2002; W. W. Chong et al., 2013; M. J. Martin et al., 2009). This is further 
supported by a meta-analysis of 12 published studies, which concluded that 
depressed patients were three times more likely to be non-adherence to treatment as 
compared to non-depressed patients (DiMatteo et al., 2000). Similarly, a qualitative 
analyses of four focus groups of patients (N=30) found that sense of isolation as 
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being nature of depression itself; which may have contributed to patients’ refusal to 
adhere to their antidepressants (Uebelacker et al., 2012).  
 
A study conducted by De las Cuevas et al. (2014) found that severity of depression 
was related to patients’ poor adherence. Beck Depression Inventory-II (BDI-II) was 
used to measure the severity of patients’ depression in the study. The study findings 
showed that patients who were adherence were those who had less severe depression 
(BDI-II score: 18, mild) than that of patients who were non-adherence (BDI-II score: 
22, moderate). Apart from that, patients with co-morbid diseases especially diabetes 
and hypertension often suffer from some form of depression due to their disease state 
(Grenard et al., 2011; Habtewold, Alemu, & Haile, 2016; Katon, 2008). It was found 
that the presence of depression lead to treatment non-adherence to patients’ co-
morbid diseases. For example, presences of depressive symptoms are associated with 
poor blood pressure control and complications of hypertension due to poor 
antihypertensive medication adherence (Krousel‐Wood & Frohlich, 2010). On the 
other hand, patients with diabetes who are depression are less likely to adhere to 
diabetes sell-care regimens than non-depressed patients, which result in increase of 
disease burden (Markowitz, Gonzalez, Wilkinson, & Safren, 2011).  
 
In conclusion, all of the studies found that patient-specific factors (antidepressants 
are addictive, forgetfulness, and patients’ attitudes and beliefs), medication-specific 
factors (adverse effects of antidepressants), socio-cultural related factors (stigma, and 
lack of support network), healthcare provision and system related factors (poor 
patient-provider relationship, long distance from home to hospital, and long waiting 
time at the clinic), and disease related factors (depression severity and disease co-
